BASF Pharma Ingredients and Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BASF Pharma Ingredients and Services

The innovative PeroXeal™ packaging concept sets new standards in the market by protecting BASF’s PVP-based excipients (marketed under the trade name Kollidon®) from environmental influences such as atmospheric oxygen. Thanks to the new packaging, which applies established barrier technologies to the needs of the pharmaceutical ingredient market, Kollidon’s peroxide content can be reduced to a level comparable with that of naturally-based raw materials. This significantly increases stability and ensures consistent performance – and makes Kollidon a viable alternative to cellulose when working with oxygen-sensitive ingredients.

As the packaging extends Kollidon’s retest period to up to four years, customers benefit from increased flexibility in the planning, handling and shipping of goods. Additionally, the longer shelf life helps mitigate risk and provides a greater safety margin.

The PeroXeal packaging concept is a combination of multiple film layers complemented by inert gas flushing and heat sealing. The foil comprises three distinct functional layers, each specifically designed to shield the product from environmental influences. The transparent inner lining is compatible with non-invasive NIR testing – so packaging remains airtight until the product is put to use.

A large number of Kollidon products are already available in PeroXeal packaging – at no additional cost to the customer.

Contact details

www.kollidon.com/kollidon/PeroXealconcept.aspx?
pharma-ingredients@basf.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
FindPharma Custom Search

Click here